Insider filing · ASMB

Gilead Sciences, Inc. bought $55.0M of Assembly Biosciences (ASMB)

Executed Aug 8 2025, disclosed Oct 3 2025, 56 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Oct 3 2025), the stock returned +30.6% (delay-adjusted); from the execution session (Aug 8 2025), +7.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

GI Gilead Sciences, Inc. 10% owner profile →

Gilead Sciences, Inc. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ASMB. Across 1 priced purchase filing, the average 21-session return was +7.0% from execution and +30.6% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 56 days.

ASMB ASMB ASMB · 4 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→